Cancer
Researchers at Cedars-Sinai Medical Center have highlighted the challenges in using CAR-T cell therapy for treating solid tumors, including the unique immune microenvironment of these tumors. The study emphasizes the need for optimizing CAR-T cell functionality and adaptability to improve the therapy's effectiveness. Specifically, the research focuses on
Cancer
Research findings on artificial intelligence (AI) and machine learning (ML) applications in cancer immunotherapy have made significant progress in addressing the complex interplay between cancer and the immune system. A new report from the City of Hope National Medical Center in Duarte, California, highlights the potential of AI technologies in
Cancer
Research investigators have developed new antibody-gamma delta (gd) T cell conjugates that hold great promise in adoptive cell therapy, a promising approach to cancer treatment. The new conjugates are designed to enhance tumor-targeting efficiency and induce cancer cell pyroptosis. A team of researchers from Peking University conducted the study, which
Biochemistry
Researchers from Tongji University have discovered a new biomarker for predicting the response to immunotherapy in non-small cell lung cancer (NSCLC). By analyzing the correlations between MED12 nonsynonymous mutations and survival, clinical, genomic, transcriptomic information, and immune infiltration information, the team identified MED12 as a significant predictor of immunotherapy outcome.
Biochemistry
Researchers at Kumamoto University have made significant progress in understanding the human T-cell leukemia virus type 1 (HTLV-1) pathogenesis, a hematological malignancy with a poor prognosis. By employing high-throughput sequencing and advanced molecular techniques, the study has enabled the analysis of clonal dynamics and proviral structure in HTLV-1-infected cells. This
Biochemistry
Researchers at Deka Biosciences Inc. have made a significant discovery in cancer treatment, coupling IL-2 with IL-10 to mitigate toxicity and enhance anti-tumor immunity. According to the study, published in Cell Reports Medicine, this combination prevents toxicity while retaining cytotoxic T cell activation and limiting regulatory T cell expansion. The
Cancer
The Euro 8 million European initiative, led by Bar-Ilan University, aims to decentralize the production of CAR-T cell therapy, a cutting-edge treatment for cancer, by developing a fully automated system that allows hospitals to manufacture the therapy on-site in just 24 hours. This project, called EASYGEN, will bring advanced gene
Cancer
Researchers at the International Islamic University in Islamabad, Pakistan, have made a groundbreaking discovery in the field of oncology, identifying 16 novel markers of cancer and T-cells associated with pancreatic ductal adenocarcinoma (PDAC). The study employed single-cell RNA sequencing (scRNA-seq) analysis to uncover the underlying mechanisms of T-cell exhaustion, which
Cancer
A new study published in the journal Cell Reports Medicine reveals that zeaxanthin, a plant-derived carotenoid found in leafy greens and corn, may have a significant impact on the body's cancer-fighting immune cells. The research shows that zeaxanthin can enhance the ability of CD8+ T cells to attack
Cancer
Alligator Bioscience has announced the publication of a peer-reviewed article in Cancer Immunology Research, a journal of the American Association for Cancer Research (AACR). The paper presents preclinical data on ATOR-4066, a bispecific antibody targeting CD40 and CEACAM5 developed using Alligator's proprietary Neo-X-Prime platform and RUBY format. The
Cancer
Researchers at Indiana University School of Medicine have developed a novel method to transform immunosuppressive cells within tumors into cancer fighters. This groundbreaking approach, published in Science Immunology, has the potential to revolutionize treatments for aggressive cancers such as triple-negative breast cancer, colorectal cancer, and melanoma. By targeting the FOXP3
Cancer
Tampa General Hospital (TGH) has received accreditation from the Foundation for the Accreditation of Cellular Therapy (FACT) for its cellular therapy program, which includes immune effector cell therapy and stem cell transplants to treat patients with aggressive blood cancers. This accreditation represents a gold seal of quality and safety in
